Abstract: The application relates to a method, device and storage medium for measuring palpebral fissure height. The method comprises capturing the first eye position image of the user looking straight ahead in a near-infrared light field of 700-1200 nm at the position in front of the eye; and segmenting the background, the iris, the sclera and the pupil from the first eye position image by the training method of a neural network. The pupil center was extracted from the segmented pupil, and the vertical pupil center line was obtained. The distance between the junction point of the sclera, the iris or the pupil on the center line of the pupil and the background is obtained, and the palpebral fissure height is calculated using the distance.

Abstract: Provided are an Akkermansia muciniphila strain and use thereof in preventing and treating metabolic diseases. This strain is named Akkermansia muciniphila SSYD-3 and the accession number thereof is CGMCC No. 14764. This strain is more ideal than the existing Akkermansia strain ATCC BAA835 in respect of fermentation performance, storage stability, acid and bile resistance, and the effect on treating metabolic diseases.

Abstract: The present disclosure belongs to the technical field of medicine, and relates to a use of a GABAA receptor as a target in the preparation or screening of a drug for reducing blood lipid, treating obesity, and/or improving metabolism. The present disclosure provides a use of a GABAA receptor as a target in the preparation or screening of a drug with one or more functions selected from the group consisting of functions (1) to (4): (1) reducing blood lipid; (2) treating obesity; (3) improving metabolic syndrome; and (4) inhibiting small intestinal lipid absorption. The GABAA receptor is closely related to a lipid absorption ability of a small intestine, and the use of the present disclosure provides a new drug target and a new therapeutic means for treating obesity, reducing blood lipid, and improving metabolism.

Abstract: A radiomic biomarker determination method and system for assessment of the risk of metabolic diseases. The method includes: obtaining abdominal & pelvic volumetric computed tomography (CT) scan from the given subject; determining the fat area to be analyzed from the CT scan, separating visceral fat using an image segmentation method, and normalizing the visceral fat area under physical scale; extracting N imaging features of the visceral fat; selecting n optimal imaging features from the N candidate features; dividing the normalized visceral fat area into multiple visceral fat blocks with equal thickness; extracting n corresponding optimal imaging features from each visceral fat block, named as block imaging features; and determining the representative visceral fat block from the candidate blocks and taking the representative visceral fat block and the (block) imaging features extracted from the representative visceral fat block as radiomic biomarkers.

Abstract: A power supply apparatus wake-up circuit is provided. The power supply apparatus wake-up circuit includes a power consumption control circuit and a wake-up circuit connected to the power consumption control circuit. The power consumption control circuit includes a voltage regulation module and a protection circuit connected to the voltage regulation module. The voltage regulation module adjusts a voltage output to the protection circuit according to a sleep control signal. The protection circuit determines whether to trigger over-discharge protection according to an input voltage. The wake-up circuit includes a first switching device, and the wake-up circuit outputs a wake-up control signal to the protection circuit based on an operation of the first switching device by a user such that the protection circuit stops triggering the over-discharge protection.

Abstract: The present application relates to a technical field of semiconductors, and discloses a device having a physically unclonable function, a method for manufacturing same, and a chip using same.

Abstract: Provided are an Akkermansia muciniphila strain and use thereof in preventing and treating metabolic diseases. This strain is named Akkermansia muciniphila SSYD-3 and the accession number thereof is CGMCC No. 14764. This strain is more ideal than the existing Ackermannia strain ATCC BAA835 in respect of fermentation performance, storage stability, acid and bile resistance, and the effect on treating metabolic diseases.

Abstract: The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet ?-cell function, and type 2 diabetes mellitus.

Abstract: A power supply apparatus wake-up circuit is provided. The power supply apparatus wake-up circuit includes a power consumption control circuit and a wake-up circuit connected to the power consumption control circuit. The power consumption control circuit includes a voltage regulation module and a protection circuit connected to the voltage regulation module. The voltage regulation module adjusts a voltage output to the protection circuit according to a sleep control signal. The protection circuit determines whether to trigger over-discharge protection according to an input voltage. The wake-up circuit includes a first switching device, and the wake-up circuit outputs a wake-up control signal to the protection circuit based on an operation of the first switching device by a user such that the protection circuit stops triggering the over-discharge protection.

Abstract: The present application relates to a technical field of semiconductors, and discloses a device having a physically unclonable function, a method for manufacturing same, and a chip using same.

Abstract: The present application relates to a technical field of semiconductors, and discloses a device having a physically unclonable function, a method for manufacturing same, and a chip using same.

Abstract: An infusion pump is disclosed comprising control unit, container, actuation unit and detection unit. The container can store medicinal liquid for treating hypogonadotropic hypogonadism. The control unit can receive external control signal comprising infusion interval, concentration of medicinal liquid and dose of medicament for treating hypogonadotropic hypogonadism at each infusion. The control unit is configured to activate actuation unit based on infusion interval to cause medicinal liquid to flow out of container. The detection unit can detect output of medicinal liquid from container and feed it back to control unit. The control unit is configured to activate actuation unit based on dose at each infusion, concentration of medicinal liquid and fed-back output of medicinal liquid. According to the invention, sustained, automatic infusions of the medicament for treating hypogonadotropic hypogonadism are allowed without patient intervention.

Abstract: Disclosed are three benign thyroid nodule-specific genes SPOP, EZH1 and ZNF148 and the use thereof in the detection of benign thyroid nodules. Also provided are a method for detecting benign thyroid nodules and a corresponding detection kit.

Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.

Abstract: A method and a composition for improving gut micro biota structure, selectively increase a first gut microbiota population while simultaneously decrease a second gut micro biota population in a subject. The first gut micro biota population includes a short-chain fatty acid (SCFA)-producing bacterium and the second gut microbiota population includes an endotoxin-producing bacterium.

Abstract: The present application relates to a technical field of semiconductors, and discloses a device having a physically unclonable function, a method for manufacturing same, and a chip using same.

Abstract: An intestinal microorganism metagenomic feature is a bacteroid intestinal pattern. By using the intestinal metagenomic pattern, it was found that type 2 diabetic patients with different intestinal parasitic bacterial flora had remarkably different responses to treatment with the diabetic hypoglycemic drug acarbose. Therefore, before treatments, the intestinal patterns of the patients can be assessed to select those patients likely to experience optimal curative effects, and to determine whether acarbose is suitable for the treatment of individual patients with type 2 diabetes. In addition, while intestinal patterns are conventionally distinguished by DNA sequencing or PCT amplification of parasitic bacteria in excrements, the intestinal patterns can be well distinguished using a bile acid composition, especially secondary bile acids, under baseline conditions. The intestinal patterns can be identified through markers in blood, and then be used as markers for diagnosis.

Abstract: An infusion pump is disclosed comprising control unit, container, actuation unit and detection unit. The container can store medicinal liquid for treating hypogonadotropic hypogonadism. The control unit can receive external control signal comprising infusion interval, concentration of medicinal liquid and dose of medicament for treating hypogonadotropic hypogonadism at each infusion. The control unit is configured to activate actuation unit based on infusion interval to cause medicinal liquid to flow out of container. The detection unit can detect output of medicinal liquid from container and feed it back to control unit. The control unit is configured to activate actuation unit based on dose at each infusion, concentration of medicinal liquid and fed-back output of medicinal liquid. According to the invention, sustained, automatic infusions of the medicament for treating hypogonadotropic hypogonadism are allowed without patient intervention.

Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity-related diseases, and a method for treatment or prevention of obesity-related diseases.

Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.